Background In recent years, signifcant eforts have been directed towards the research and development of disease-modifying therapies for dementia. These drugs focus on prodromal (mild cognitive impairment, MCI) and/ or early stages of Alzheimer’s disease (AD). Literature evidence indicates that a considerable proportion of individuals with MCI do not progress to dementia. Identifying individuals at higher risk of developing dementia is essential for appropriate management, including the prescription of new disease-modifying therapies expected to become available in clinical practice in the near future. Methods The ongoing INTERCEPTOR study is a multicenter, longitudinal, interventional, non-therapeutic cohort study designed to enroll 500 individuals with MCI aged 50–85 years. The primary aim is to identify a biomarker or a set of biomarkers able to accurately predict the conversion from MCI to AD dementia within 3 years of follow-up. The biomarkers investigated in this study are neuropsychological tests (mini-mental state examination (MMSE) and delayed free recall), brain glucose metabolism ([18F]FDG-PET), MRI volumetry of the hippocampus, EEG brain connectivity, cerebrospinal fuid (CSF) markers (p-tau, t-tau, Aβ1-42, Aβ1-42/1–40 ratio, Aβ1-42/p-Tau ratio) and APOE genotype. The baseline visit includes a full cognitive and neuropsychological evaluation, as well as the collection of clinical and socio-demographic information. Prognostic models will be developed using Cox regression, incorporating individual characteristics and biomarkers through stepwise selection. Model performance will be evaluated in terms of discrimination and calibration and subjected to internal validation using the bootstrapping procedure. The fnal model will be visually represented as a nomogram. Discussion This paper contains a detailed description of the statistical analysis plan to ensure the reproducibility and transparency of the analysis. The prognostic model developed in this study aims to identify the population
Development of a prediction model of conversion to Alzheimer’s disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project / Lombardo, Flavia L.; Lorenzini, Patrizia; Mayer, Flavia; Massari, Marco; Piscopo, Paola; Bacigalupo, Ilaria; Ancidoni, Antonio; Sciancalepore, Francesco; Locuratolo, Nicoletta; Remoli, Giulia; Salemme, Simone; Cappa, Stefano; Perani, Daniela; Spadin, Patrizia; Tagliavini, Fabrizio; Redolfi, Alberto; Cotelli, Maria; Marra, Camillo; Caraglia, Naike; Vecchio, Fabrizio; Miraglia, Francesca; Rossini, Paolo Maria; Vanacore, Nicola; Belfiglio, Maurizio; Muscio, Cristina; Quaranta, Davide; Cassetta, Emanuele; Barbagallo, Mario; Gabelli, Carlo; Luzzi, Simona; Lauretani, Fulvio; Rainero, Innocenzo; Ferrarese, Carlo; Zanetti, Orazio; Marcon, Michela; Nobili, Flavio Mariano; Pelliccioni, Giuseppe; Capellari, Sabina; Sinforiani, Elena; Tedeschi, Gioacchino; Gerace, Carmen; Bonanni, Laura; Sorbi, Sandro; Parnetti, Lucilla; Null, Null. - In: DIAGNOSTIC AND PROGNOSTIC RESEARCH. - ISSN 2397-7523. - 8:1(2024). [10.1186/s41512-024-00172-6]
Development of a prediction model of conversion to Alzheimer’s disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project
Lorenzini, Patrizia;Mayer, Flavia;Massari, Marco;Piscopo, Paola;Ancidoni, Antonio;Sciancalepore, Francesco;Locuratolo, Nicoletta;Remoli, Giulia;Salemme, Simone;Cappa, Stefano;Vecchio, Fabrizio;Miraglia, Francesca;Vanacore, Nicola;Luzzi, Simona;
2024
Abstract
Background In recent years, signifcant eforts have been directed towards the research and development of disease-modifying therapies for dementia. These drugs focus on prodromal (mild cognitive impairment, MCI) and/ or early stages of Alzheimer’s disease (AD). Literature evidence indicates that a considerable proportion of individuals with MCI do not progress to dementia. Identifying individuals at higher risk of developing dementia is essential for appropriate management, including the prescription of new disease-modifying therapies expected to become available in clinical practice in the near future. Methods The ongoing INTERCEPTOR study is a multicenter, longitudinal, interventional, non-therapeutic cohort study designed to enroll 500 individuals with MCI aged 50–85 years. The primary aim is to identify a biomarker or a set of biomarkers able to accurately predict the conversion from MCI to AD dementia within 3 years of follow-up. The biomarkers investigated in this study are neuropsychological tests (mini-mental state examination (MMSE) and delayed free recall), brain glucose metabolism ([18F]FDG-PET), MRI volumetry of the hippocampus, EEG brain connectivity, cerebrospinal fuid (CSF) markers (p-tau, t-tau, Aβ1-42, Aβ1-42/1–40 ratio, Aβ1-42/p-Tau ratio) and APOE genotype. The baseline visit includes a full cognitive and neuropsychological evaluation, as well as the collection of clinical and socio-demographic information. Prognostic models will be developed using Cox regression, incorporating individual characteristics and biomarkers through stepwise selection. Model performance will be evaluated in terms of discrimination and calibration and subjected to internal validation using the bootstrapping procedure. The fnal model will be visually represented as a nomogram. Discussion This paper contains a detailed description of the statistical analysis plan to ensure the reproducibility and transparency of the analysis. The prognostic model developed in this study aims to identify the populationFile | Dimensione | Formato | |
---|---|---|---|
Lombardo_et_al-2024-Diagnostic_and_Prognostic_Research.pdf
accesso aperto
Note: Lombardo_Development of a prediction model_2024
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
832.88 kB
Formato
Adobe PDF
|
832.88 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.